Hsbc Holdings PLC Has $887,000 Position in Integra LifeSciences Holdings Corporation $IART

Key Points

• Hsbc Holdings PLC significantly increased its stake in Integra LifeSciences Holdings Corporation by 303.6% in Q1, now owning 40,323 shares valued at $887,000.
• Multiple hedge funds have also adjusted their positions in Integra, with some increasing stakes significantly, highlighting institutional interest, as they collectively own 84.78% of the company's shares.
• Integra LifeSciences recently reported EPS of $0.45, exceeding estimates, but experienced a year-over-year revenue decline of 0.6% despite a favorable earnings outlook for FY 2025.

Hsbc Holdings PLC grew its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 303.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,323 shares of the life sciences company's stock after purchasing an additional 30,331 shares during the period. Hsbc Holdings PLC owned about 0.05% of Integra LifeSciences worth $887,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Arizona State Retirement System raised its position in shares of Integra LifeSciences by 4.2% in the 1st quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock valued at $437,000 after buying an additional 795 shares in the last quarter. Envestnet Asset Management Inc. grew its position in shares of Integra LifeSciences by 4.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company's stock valued at $605,000 after buying an additional 1,204 shares during the last quarter. Sei Investments Co. increased its position in Integra LifeSciences by 7.4% during the 1st quarter. Sei Investments Co. now owns 20,351 shares of the life sciences company's stock valued at $451,000 after purchasing an additional 1,398 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Integra LifeSciences by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after buying an additional 1,437 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of Integra LifeSciences by 5.3% in the 4th quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company's stock worth $947,000 after acquiring an additional 2,111 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Stock Up 2.2%

Integra LifeSciences stock traded up $0.34 during trading hours on Friday, hitting $15.99. The stock had a trading volume of 276,271 shares, compared to its average volume of 1,046,021. The stock's 50-day moving average price is $13.32 and its 200-day moving average price is $15.83. Integra LifeSciences Holdings Corporation has a 12-month low of $11.06 and a 12-month high of $27.13. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $1.25 billion, a P/E ratio of -2.45, a price-to-earnings-growth ratio of 0.85 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million during the quarter, compared to analyst estimates of $395.06 million. During the same period last year, the company earned $0.63 EPS. Integra LifeSciences's quarterly revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, JMP Securities cut their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and an average target price of $18.43.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.